Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600)

HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600)

HRS-4729 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HRS-4729
Population
obesity
Phase
1
Participants
60
Duration
12 weeks
Registry
NCT06762600

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
12 mgobesity china1260——−16.0 % vs −5.4 %
estimand not specified
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (1)
  • 12 mg · weight_unsp · press release
    participants receiving multiple doses of 12 mg of HRS-4729 achieved a mean weight loss of up to 16.0% from baseline, compared to 5.4% with placebo.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs-4729-phase-1-sad-mad-mad-part/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.